Table 2. Uni- and multivariate analyses of overall survival (OS).
|
Univariate analysis |
Multivariate analysis |
|||||
|---|---|---|---|---|---|---|
| Median OS (months) | 95% CI | P value | HR | 95% CI | P value | |
| Sex | 0.003 | 0.25 | ||||
| Female | 60 | 56.37–63.62 | — | — | ||
| Male | 50 | 46.4–53.59 | ||||
| Mutation | <0.0001 | |||||
| WT | 55 | 51.42–58.57 | — | — | — | |
| EGFR | 67 | 59.43–74.57 | ||||
| KRAS | 43 | 39.53–46.47 | ||||
| Mutation | <0.0001 | |||||
| KRAS G12V | 26 | 20.99–31 | 2.1 | 1.31–3.37 | 0.002 | |
| Non-KRAS G12V | 60 | 56.56–63.44 | ||||
| Nodal status | 0.001 | 0.68 | ||||
| N0 | 55 | 49.79–60.2 | — | — | ||
| N+ | 50 | 44.22–55.78 | ||||
| pT | <0.0001 | 0.11 | ||||
| 1 | 50 | 41.39–58.61 | — | — | ||
| 2 | 60 | 56.37–63.63 | ||||
| 3 | 48 | 41.85–54.15 | ||||
| 4 | 48 | 41.82–54.17 | ||||
| Angioinvasion | <0.0001 | |||||
| Yes | 46 | 41.83–50.17 | 0.58 | 0.34–0.99 | 0.05 | |
| No | 60 | 55.94–64.05 | ||||
| Smoking habit | <0.0001 | |||||
| Never | 64 | 59.75–68.24 | — | — | 0.06 | |
| Past | 54 | 48.69–50.3 | ||||
| Current | 48 | 45.16–50.84 | ||||
| Neo-adjuvant treatment | 0.002 | |||||
| Yes | 48 | 43.47–52.53 | — | — | 0.58 | |
| No | 59 | 54–63.99 | ||||
| Type of neo-adjuvant treatment | 0.001 | |||||
| Chemo. | 48 | 44.1–51.89 | — | — | — | |
| RT chemo. | 54 | 44.81–63.18 | ||||
| Adjuvant treatment | 0.002 | |||||
| Yes | 50 | 44.33–55.66 | — | — | 0.61 | |
| No | 55 | 49.62–60.37 | ||||
| Type of adjuvant treatment | 0.015 | |||||
| RT | 58 | 38.66–77.34 | — | — | — | |
| Chemo. | 50 | 43.86–56.13 | ||||
| RT chemo. | 50 | 42.67–57.33 | ||||
| CCI | 0.09 | |||||
| 0 | 60 | 56.75–63.25 | — | — | 0.52 | |
| 1 | 55 | 50.19–59.81 | ||||
| 2 | 60 | 51.93–68.07 | ||||
| 3 | 48 | 45.45–50.54 | ||||
| Type of resection | <0.0001 | |||||
| Seg. | 44 | 38.88–49.12 | — | — | 0.09 | |
| Lob. | 53 | 50.01–55.99 | ||||
| Bi-lob. | NR | NR | ||||
| Pneum. | 62 | 51.97–72.03 | ||||
| Skip N | 0.67 | |||||
| Yes | 62 | — | — | — | — | |
| No | 62 | 58.12–65.88 | ||||
| Microscopic N | 0.05 | |||||
| Yes | 62 | 48.02–75.98 | — | — | 0.62 | |
| No | 45 | 40.45–49.54 | ||||
| Number of N2 stations involved | 0.45 | |||||
| 1 | 60 | 57.99–62.01 | — | — | — | |
| 2 | 65 | 40.93–89.07 | ||||
| R0 | 54 | 51.09–56.91 | 0.59 | — | — | — |
| R1 | 58 | 43.22–72.77 | ||||
Abbreviations: Bi-lob=bi-lobectomy; chemo=chemotherapy; CI=confidence interval; CCI=Charlson comorbidity index; HR=hazard ratio; Lob=lobectomy; NR=not reached; OS=overall survival; Pneum=pneumonectomy; RT=radiotherapy; Seg=segmentectomy; WT=wild type.
Because neo-adjuvant treatment and adjuvant treatment correlated with the type of treatment performed (i.e., radiotherapy, chemotherapy or radio-chemotherapy), the type of treatment was excluded from multivariate analyses. Because KRAS G12V and mutational status correlated, only KRAS G12V status was entered in the multivariate model. Non-KRAS G12V included wild-type, EGFR mutants and KRAS non-G12V patients.